ArticleJournal of gastrointestinal cancer2023
The Anticancer Effect of a Conjugated Antimicrobial Peptide Against Colorectal Cancer (CRC) Cells.
Article in Journal of gastrointestinal cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- A Serum-Stable Antimicrobial Peptide-Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Engineered Anti-Microbial Peptides Inhibit Cell Viability, Promote Apoptosis, and Induce Cell Cycle Arrest in SW620 Human Colon Adenocarcinoma Cells.Current protein & peptide science · 2025Article
- Intestinal Dysbiosis: Microbial Imbalance Impacts on Colorectal Cancer Initiation, Progression and Disease Mitigation.Biomedicines · 2024Review
- Application Value of Antimicrobial Peptides in Gastrointestinal Tumors.International journal of molecular sciences · 2023Review
- The Effect of LL37 Antimicrobial Peptide on FOXE1 and lncRNA PTCSC 2 Genes Expression in Colorectal Cancer (CRC) and Normal Cells.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Peptide therapeutics in the management of metastatic cancers.RSC advances · 2022Review
- A Concise Review on the Role of Natural and Synthetically Derived Peptides in Colorectal Cancer.Current topics in medicinal chemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough antimicrobial peptides (AMPs) were initially known as compounds of the innate immune system to fight microbial pathogens, it has been recently proposed that differences in normal and cancer cell membranes cause the anticancer effect of these peptides. The aim of this study was to evaluate the anticancer effect of MELITININ+BMAP27-conjugated peptide against colorectal cancer (CRC) cells.
methodsThe MELITININ+BMAP27-conjugated peptides were designed and the β-naphthylalanine residues were added to the termini to improve the anticancer effect. CRC cancer cell lines including HT29, SW742, HCT-116, and WiDr were used. After preparing concentrations of 5, 10, 25, 50, 100, 150, 200, and 400 μg/mL of peptide solution, the rate of cell death after 12, 24, and 48 h was assessed using MTT test. After confirmation of the 30 µg/mL efficacy and nontoxic concentration, the cells were exposed to this concentration, and the total RNA was extracted. The quantitative real-time PCR (RT-qPCR) technique was performed for the amplification of Bax, caspase3, atg5, and GAPDH (glyceraldehyde 3-phosphate dehydrogenase as the internal control) genes.
resultsThe cytotoxicity of peptide against normal cells exhibited that the IC50 at 24 and 4 h included 80 and 100 µg/mL, respectively. After 24-72 h of treatment, a significant difference in the mean percentage of CRC living cells was observed at concentrations of 50-400 μg/mL of conjugated peptide (p < 0.05). The IC50 of the peptide at 24, 48, and 72 h of exposure was measured as 30, 20, and 10 μg/mL, respectively. The peptide resulted in a significant increase of 2.35-fold in the mean expression of Bax gene in CRC cells (p < 0.001). It also caused a significant increase of 1.75 times (p = 0.0112) of caspase 3 gene and 1.2 times (p = 0.0217) of atg5 gene. There was no significant difference among cell lines regarding the expression of each gene.
conclusionThe conjugated peptide caused the death of CRC lines via induction of the apoptosis and necrosis mechanisms. More studies are needed in this regard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.